These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 16463058)
1. Gemcitabine resistance due to deoxycytidine kinase deficiency can be reverted by fruitfly deoxynucleoside kinase, DmdNK, in human uterine sarcoma cells. Jordheim LP; Galmarini CM; Dumontet C Cancer Chemother Pharmacol; 2006 Oct; 58(4):547-54. PubMed ID: 16463058 [TBL] [Abstract][Full Text] [Related]
2. Mechanisms of uptake and resistance to troxacitabine, a novel deoxycytidine nucleoside analogue, in human leukemic and solid tumor cell lines. Gourdeau H; Clarke ML; Ouellet F; Mowles D; Selner M; Richard A; Lee N; Mackey JR; Young JD; Jolivet J; Lafrenière RG; Cass CE Cancer Res; 2001 Oct; 61(19):7217-24. PubMed ID: 11585758 [TBL] [Abstract][Full Text] [Related]
3. Acquisition of chemoresistance to gemcitabine is induced by a loss-of-function missense mutation of DCK. Nakano T; Saiki Y; Kudo C; Hirayama A; Mizuguchi Y; Fujiwara S; Soga T; Sunamura M; Matsumura N; Motoi F; Unno M; Horii A Biochem Biophys Res Commun; 2015 Sep; 464(4):1084-1089. PubMed ID: 26196746 [TBL] [Abstract][Full Text] [Related]
4. Detection of an alternatively spliced form of deoxycytidine kinase mRNA in the 2'-2'-difluorodeoxycytidine (gemcitabine)-resistant human ovarian cancer cell line AG6000. Al-Madhoun AS; van der Wilt CL; Loves WJ; Padron JM; Eriksson S; Talianidis I; Peters GJ Biochem Pharmacol; 2004 Aug; 68(4):601-9. PubMed ID: 15276067 [TBL] [Abstract][Full Text] [Related]
5. Resistance to gemcitabine in a human follicular lymphoma cell line is due to partial deletion of the deoxycytidine kinase gene. Galmarini CM; Clarke ML; Jordheim L; Santos CL; Cros E; Mackey JR; Dumontet C BMC Pharmacol; 2004 May; 4():8. PubMed ID: 15157282 [TBL] [Abstract][Full Text] [Related]
6. Downregulation of deoxycytidine kinase in cytarabine-resistant mantle cell lymphoma cells confers cross-resistance to nucleoside analogs gemcitabine, fludarabine and cladribine, but not to other classes of anti-lymphoma agents. Klanova M; Lorkova L; Vit O; Maswabi B; Molinsky J; Pospisilova J; Vockova P; Mavis C; Lateckova L; Kulvait V; Vejmelkova D; Jaksa R; Hernandez F; Trneny M; Vokurka M; Petrak J; Klener P Mol Cancer; 2014 Jun; 13():159. PubMed ID: 24972933 [TBL] [Abstract][Full Text] [Related]
7. Induction of resistance to 2',2'-difluorodeoxycytidine in the human ovarian cancer cell line A2780. Ruiz van Haperen VW; Veerman G; Eriksson S; Stegmann AP; Peters GJ Semin Oncol; 1995 Aug; 22(4 Suppl 11):35-41. PubMed ID: 7481843 [TBL] [Abstract][Full Text] [Related]
9. Development of gene therapy in association with clinically used cytotoxic deoxynucleoside analogues. Hébrard C; Dumontet C; Jordheim LP Cancer Gene Ther; 2009 Jul; 16(7):541-50. PubMed ID: 19343063 [TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: relationship to molecular mechanisms of gemcitabine resistance and survival. Sebastiani V; Ricci F; Rubio-Viqueira B; Kulesza P; Yeo CJ; Hidalgo M; Klein A; Laheru D; Iacobuzio-Donahue CA Clin Cancer Res; 2006 Apr; 12(8):2492-7. PubMed ID: 16638857 [TBL] [Abstract][Full Text] [Related]
11. Cross-resistance in the 2',2'-difluorodeoxycytidine (gemcitabine)-resistant human ovarian cancer cell line AG6000 to standard and investigational drugs. Bergman AM; Giaccone G; van Moorsel CJ; Mauritz R; Noordhuis P; Pinedo HM; Peters GJ Eur J Cancer; 2000 Oct; 36(15):1974-83. PubMed ID: 11000580 [TBL] [Abstract][Full Text] [Related]
12. Collateral sensitivity to gemcitabine (2',2'-difluorodeoxycytidine) and cytosine arabinoside of daunorubicin- and VM-26-resistant variants of human small cell lung cancer cell lines. Bergman AM; Munch-Petersen B; Jensen PB; Sehested M; Veerman G; Voorn DA; Smid K; Pinedo HM; Peters GJ Biochem Pharmacol; 2001 Jun; 61(11):1401-8. PubMed ID: 11331076 [TBL] [Abstract][Full Text] [Related]
13. RNAi depletion of deoxycytidine and deoxyguanosine kinase in human leukemic CEM cells. Fyrberg A; Albertioni F; Lotfi K Nucleosides Nucleotides Nucleic Acids; 2008 Jun; 27(6):712-9. PubMed ID: 18600530 [TBL] [Abstract][Full Text] [Related]
14. Is the resistance of gemcitabine for pancreatic cancer settled only by overexpression of deoxycytidine kinase? Funamizu N; Okamoto A; Kamata Y; Misawa T; Uwagawa T; Gocho T; Yanaga K; Manome Y Oncol Rep; 2010 Feb; 23(2):471-5. PubMed ID: 20043109 [TBL] [Abstract][Full Text] [Related]
15. Recombinant deoxyribonucleoside kinase from Drosophila melanogaster can improve gemcitabine based combined gene/chemotherapy for targeting cancer cells. Fatima M; Iqbal Ahmed MM; Batool F; Riaz A; Ali M; Munch-Petersen B; Mutahir Z Bosn J Basic Med Sci; 2019 Nov; 19(4):342-349. PubMed ID: 30903745 [TBL] [Abstract][Full Text] [Related]
17. [Mechanisms of the drug resistance of a 2', 2-difluorodeoxycytide (gemcitabine)-resistant variant of the human lung adenocarcinoma cell line]. Dong M; Feng FY; Lin C; Zhang XY; Fu M; Liang X; Zha YY; Lu HY; Wu M Zhonghua Yi Xue Za Zhi; 2004 Feb; 84(4):323-8. PubMed ID: 15059518 [TBL] [Abstract][Full Text] [Related]
19. DCK is frequently inactivated in acquired gemcitabine-resistant human cancer cells. Saiki Y; Yoshino Y; Fujimura H; Manabe T; Kudo Y; Shimada M; Mano N; Nakano T; Lee Y; Shimizu S; Oba S; Fujiwara S; Shimizu H; Chen N; Nezhad ZK; Jin G; Fukushige S; Sunamura M; Ishida M; Motoi F; Egawa S; Unno M; Horii A Biochem Biophys Res Commun; 2012 Apr; 421(1):98-104. PubMed ID: 22490663 [TBL] [Abstract][Full Text] [Related]